Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in thyroid cancer

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Rajoria, Shilpi ^a   Suriano, Robert ^a   George, Andrea ^a   Shanmugam, Arulkumaran ^a   Schantz, Stimson P ^b   Geliebter, Jan ^a   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GELATINASE A; GELATINASE B; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; ESTROGEN; ESTROGEN RECEPTOR ALPHA; INDOLE DERIVATIVE;

ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME RELEASE; HORMONE INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; THYROID CANCER; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; METASTASIS; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; INDOLES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; THYROID NEOPLASMS;

EID: 79251537208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015879     Document Type: Article

References (50)

1. Nikiforov YE (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21: S37-S43.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics. CA Cancer J Clin 59: 225-49.
3. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicularcell neoplasia. Nat Rev Cancer 6: 292-306.
4. Fitzgibbons SC, Brams DM, Wei JP (2008) The treatment of thyroid cancer. Am Surg 74: 389-99.
5. Tuttle RM, Leboeuf R (2008) Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37: 419-35.
6. Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86: 1447-63.
7. Ashok BT, Tiwari RK (2004) Cruciferous vegetables and cancer chemoprevention. Recent Res Dev Nutr 6: 83-94.
8. Bode AM, Dong Z (2009) Cancer prevention research - then and now. Nat Rev cancer 9: 508-16.
9. Bradlow HL, Sepkovic DW (2002) Diet and breast cancer. Ann N Y Acad Sci 963: 247-67.
10. Sarkar FH, Li Y (2009) Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35: 597-607.
11. Aggarwal BB, Ichikawa H (2005) Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4: 1201-15.
12. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP (1994) Selective Responsiveness of Human Breast Cancer Cells to Indole-3-carbinol, a Chemopreventive Agent. J Natl Cancer Inst 86: 126-31.
13. Ashok BT, Chen YG, Liu X, Garikapaty VP, Seplowitz R, et al. (2002) Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 2: S86-93.
14. Garikapaty VPS, Ashok BT, Tadi K, Mittelman A, Tiwari RK (2006) Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 66: 453-62.
15. Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, Williams DE (2003) Evaluation of chronic dietary exposure to indole-3-carbinol and absorptionenhanced 3,39-diindolylmethane in sprague-dawley rats. Toxicol Sci 74: 10-21.
16. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH (2007) Inhibition of angiogenesis and invasion by 3,39-diindolylmethane is mediated by the nuclear factor- KB downstream target genes MMP-9 & uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67: 3310-9.
17. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, et al. (2007) Inactivation of NF- KB by 3,39-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6: 2757-65.
18. Xue L, Firestone GL, Bjeldanes LF (2005) DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343-53.
19. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF (2004) Pilot study: effect of 3,39-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition Cancer 50: 161-167.
20. Smith S, Sepkovic D, Bradlow HL, Auborn KJ (2008) 3,39-Diindolylmethane and Genistein Decrease the Adverse Effects of Estrogen in LNCaP and PC-3 Prostate Cancer Cells. Journal of Nutrition 138: 2379-2385.
21. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, et al. (2010) Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20: 33-41.
22. Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK (2006) 3,39- Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 340: 718-25.
23. Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, et al. (2008) 17b- Estradiol Mobilizes Bone marrow-Derived Endothelial Progenitor Cells to Tumors. Cancer Research 68: 6038-42.
24. Husain S, Jafri F, Crosson CE (2005) Acute Effects of PGF2a on MMP-2 Secretion from Human Ciliary Muscle Cells: A PKC- and ERK-Dependent Process. Invest Ophthalmol Vis Sci 46: 1706-1713.
25. Noujaim D, Golen CM, Golen KL, Grauman A, Feldman EL (2002) N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene 21: 4549-4557.
26. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
27. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2: 329-33.
28. Gupta GP, Massagué J (2006) Cancer Metastasis: Building a Framework. Cell 127: 679-95.
29. Kamel H, Abdelazim I, Habib SM, El Shourbagy MA, Ahmed NS (2010) Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Cancer 32: 580-586.
30. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, et al. (2010) Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Research 70: 2224-34.
31. Sarkar FH, Li Y, Wang Z, Kong D (2009) Cellular signaling perturbation by natural products. Cell Signal 21: 1541-1547.
32. He YY, Cai B, Yang YX, Liu XL, Wan XP (2009) Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 100: 1051-61.
33. Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11(3): 206.
34. Ciocca DR, Fanelli MA (1997) Estrogen Receptors and Cell Proliferation in Breast Cancer. Trends in Endocrinology & Metabolism 8: 313-321.
35. Song RX, Santen RJ (2006) Membrane initiated estrogen signaling in breast cancer. Biology of Reproduction 75: 9-16.
36. Hua K, Feng W, Cao Q, Zhou X, Lu X, et al. (2008) Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 33: 959-67.
37. Pietras RJ (2003) Interaction between estrogen and growth factor receptors in human breast cancers and tumor-associated vasculature. Breast J 9: 361-73.
38. Marquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ (2006) Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 246: 91-100.
39. MacGregor JI, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-96.
40. Peng J, Sengupta S, Jordan VC (2009) Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 9: 481-99.
41. Friedl P, Wolf K (2008) Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68: 7247-9.
42. O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, et al. (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60: 1121-1128.
43. Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, et al. (2006) Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase. Endocr Relat Cancer 13: 1173-1183.
44. Nilsson U, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102: 253-261.
45. Kousidoua OC, Berdiakib A, Kletsasc D, Zafiropoulosb A, Theocharisa AD, et al. (2008) Estradiol-estrogen receptor: A key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncology 2: 223-232.
46. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, et al. (2010) Mesenchymal stem cells enhance growth and metastasis of colon cancer. International Journal of Cancer 127: 2323-2333.
47. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, et al. (2001) Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61: 5985-5991.
48. Manavathi B, Kumar R (2006) Steering estrogen signals from the plasma membrane to the nucleus: Two sides of the coin. J Cell Physiol 207: 594-604.
49. Vasconsuelo A, Milanesi L, Boland R (2008) 17-beta-estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidyl inositol 3-kinase/Akt pathway. J Endocrinol 196: 385-397.
50. Sanchez M, Sauve K, Picard N, Tremblay A (2007) The hormonal response of estrogen receptor beta is decreased by the PI3K/Akt pathway via a phosphorylation-dependent release of CREB-binding protein. J Biol Chem 282: 4830-4840.